Who we are

At Soteria Biotherapeutics, we are developing a next generation of bispecific T-cell engagers to treat patients with solid tumor cancers. Soteria’s highly innovative T-LITE™ platform provides small molecule-dependent activation of bispecific antibody therapies, enabling safer and more efficacious treatments through pulsatile activity, reduced side effects and higher dosing. Our mission is to safely harness the body’s natural immune system to defeat cancer and transform patients’ lives.

The company was founded in 2018 by Jim Wells, PhD, renowned protein engineer and professor at UC San Francisco, Zachary Hill, PhD, and Alexander Martinko, PhD. The company has exclusively licensed technology from UC San Francisco based on the work of Drs. Wells, Hill and Martinko.

LEADERSHIP

Kristine Ball

CHIEF EXECUTIVE OFFICER

Bhas Dani
Bhas Dani, MS, PhD

SVP, CHIEF TECHNICAL OFFICER

Zachary Hill, PhD

SVP, CHIEF SCIENTIFIC OFFICER
AND CO-FOUNDER

Mohammad Tabrizi, PhD

VP, PRECLINICAL DEVELOPMENT

BOARD OF DIRECTORS

Steven James

BOARD CHAIR

David Allison, PhD
Kristine Ball
Zachary Hill, PhD
Therese Maria Liechtenstein, PhD
Nisha Marathe, PhD
Aaron Nelson, MD, PhD
Momo Wu, PhD

SCIENTIFIC ADVISORY BOARD

Jim Wells, PhD

SAB CHAIR

Mike Briskin, PhD
Brian Daniels, MD
Larry Fong, MD
Peter Kim, PhD
Henry Lowman, PhD
Art Weiss, MD, PhD

INVESTORS